CD30: Seeing is not always believing

Blood

Volumn 125, Issue 9, 2015, Pages 1358-1359

  Blum, Kristie A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; LENALIDOMIDE; MESSENGER RNA; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTIBODY CONJUGATE; CAC10-VCMMAE; TUMOR MARKER;

ANTIGEN EXPRESSION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLISM; NEOPLASM RECURRENCE, LOCAL;

ANTIGENS, CD30; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84923913748     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-622480     Document Type: Note

References (10)

1. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
2. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
3. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394-1402.
4. Vose JM, Habermann TM, Czuczman MS, et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013;162(5):639-647.
5. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058-5066.
6. Wilson W, Gerecitano J, Goy A, et al. The bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765) has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multi-center, open-label, phase 2 study [abstract]. Blood. 2012;120(21). Abstract 623.
7. Bartlett N, Smith M, Advani R, et al. Brentuximab vedotin monotherapy in DLBCL patients with undetectable CD30: preliminary results from a phase 2 study [abstract]. Blood. 2014;124(21). Abstract 629.
8. Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983-2986.
9. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-2724.
10. Yasenchak C, Farber C, Budde L, et al. Brentuximab vedotin in combination with RCHOP as front-line therapy in patients with DLBCL: interim results from a phase 2 study [abstract]. Blood. 2014;124(21). Abstract 1745.